ロード中...
Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib
Sorafenib remains the standard care for patients with hepatocellular carcinoma (HCC) even though it has low antitumor efficacy. Protein neddylation is abnormally activated in many types of human cancer. However, whether dysregulation of neddylation is involved in HCC progression and whether targetin...
保存先:
| 出版年: | Oncol Rep |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
D.A. Spandidos
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6489087/ https://ncbi.nlm.nih.gov/pubmed/31002342 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2019.7098 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|